Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

3.

Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice.

Yamaguchi M, Ogata N, Shinoda Y, Akune T, Kamekura S, Terauchi Y, Kadowaki T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H.

Endocrinology. 2005 Jun;146(6):2620-8. Epub 2005 Feb 17.

PMID:
15718274
4.

Parathyroid hormone-dependent signaling pathways regulating genes in bone cells.

Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC.

Gene. 2002 Jan 9;282(1-2):1-17. Review.

PMID:
11814673
5.

Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.

Zhu J, Siclari VA, Liu F, Spatz JM, Chandra A, Divieti Pajevic P, Qin L.

PLoS One. 2012;7(12):e50099. doi: 10.1371/journal.pone.0050099. Epub 2012 Dec 31.

6.

Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway.

Li G, Barrett EJ, Barrett MO, Cao W, Liu Z.

Endocrinology. 2007 Jul;148(7):3356-63. Epub 2007 Apr 19.

PMID:
17446186
7.

The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.

Lombardi G, Di Somma C, Rubino M, Faggiano A, Vuolo L, Guerra E, Contaldi P, Savastano S, Colao A.

J Endocrinol Invest. 2011 Jul;34(7 Suppl):18-22. Review.

PMID:
21985975
8.

Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.

Schneider MR, Dahlhoff M, Andrukhova O, Grill J, Glösmann M, Schüler C, Weber K, Wolf E, Erben RG.

Bone. 2012 Jan;50(1):237-44. doi: 10.1016/j.bone.2011.10.019. Epub 2011 Oct 26.

PMID:
22056328
9.
10.

Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.

Walker EC, Poulton IJ, McGregor NE, Ho PW, Allan EH, Quach JM, Martin TJ, Sims NA.

J Bone Miner Res. 2012 Apr;27(4):902-12. doi: 10.1002/jbmr.1506.

11.

Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis.

Perrini S, Natalicchio A, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Leonardini A, Martemucci S, Belsanti G, Miccoli S, Ciampolillo A, Corrado A, Cantatore FP, Giorgino R, Giorgino F.

Endocrinology. 2008 Mar;149(3):1302-13. Epub 2007 Dec 13.

PMID:
18079194
12.

Alcohol impairs insulin and IGF-I stimulation of S6K1 but not 4E-BP1 in skeletal muscle.

Kumar V, Frost RA, Lang CH.

Am J Physiol Endocrinol Metab. 2002 Nov;283(5):E917-28.

PMID:
12376318
13.

Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.

Li C, Xing Q, Yu B, Xie H, Wang W, Shi C, Crane JL, Cao X, Wan M.

J Bone Miner Res. 2013 Oct;28(10):2094-108. doi: 10.1002/jbmr.1962.

14.

Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.

Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A.

J Clin Invest. 1997 Jun 15;99(12):2961-70.

15.

N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action.

Revollo L, Kading J, Jeong SY, Li J, Salazar V, Mbalaviele G, Civitelli R.

J Bone Miner Res. 2015 Feb;30(2):274-85. doi: 10.1002/jbmr.2323.

16.

Endogenous FGF-2 is critically important in PTH anabolic effects on bone.

Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetschman T, Hurley MM.

J Cell Physiol. 2009 Apr;219(1):143-51. doi: 10.1002/jcp.21661.

18.

Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment.

Niziolek PJ, Murthy S, Ellis SN, Sukhija KB, Hornberger TA, Turner CH, Robling AG.

J Cell Physiol. 2009 Dec;221(3):579-85. doi: 10.1002/jcp.21887.

19.

Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells.

Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ.

Mol Endocrinol. 2002 Aug;16(8):1931-42.

PMID:
12145346
20.

Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells.

Nakao Y, Koike T, Ohta Y, Manaka T, Imai Y, Takaoka K.

Bone. 2009 May;44(5):872-7. doi: 10.1016/j.bone.2009.01.370. Epub 2009 Jan 31.

PMID:
19442611

Supplemental Content

Support Center